Prognostic factors impacting survival for patients undergoing combined sorafenib–TACE therapy for HCC include established indicators such as BCLC stage, Child–Pugh class, and ECOG performance status score, while other metrics include maximum tumor size, tumor number, alpha-fetoprotein concentrations, metastasis/vascular invasion, extrahepatic spread, and sorafenib treatment duration [135,136]. Here, AFP is linked to neoplasm.